Teva Pharmaceuticals Industries Limited is identified as one of the 9 most undervalued pharma stocks to buy right now. Bank of America raises TEVA’s target to $32, while Barclays initiates an overweight rating with a $35 target, citing confidence in TEVA’s growth drivers.

Analysts are optimistic about TEVA’s pipeline progress, with a recent NDA submission for olanzapine long-acting injectable for schizophrenia. TEVA is a global leader in generics with a growing portfolio of specialty medicines.

While TEVA presents investment risks and potential, some AI stocks may offer higher returns in a shorter time frame. For more promising AI stocks, a report on the cheapest AI stock with 10,000% upside potential is available.

Read more about 13 Best Blue Chip Stocks to Buy Under $50 and 11 Best Low Priced Dividend Stocks to Buy According to Analysts. No disclosures.

Read more at Yahoo Finance: BofA Raises Teva Pharmaceuticals Industries Limited (TEVA) Target to $32 as Barclays Initiates Overweight